Impact of Acquired FXIII Deficiency on Morbidity and Mortality
NCT04416594 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2020-06-05
Summary
Observational prospective study aiming to assess acquired FXIII deficiency implications in morbidity and mortality
Conditions
- Acquired Factor XIII Deficiency Disease
Interventions
- OTHER
-
Data collection
Only data collection
Sponsors & Collaborators
-
Patricia Duque González
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-09-10
- Primary Completion
- 2020-02-12
- Completion
- 2020-05-18
Countries
- Spain
Study Locations
More Related Trials
-
Safety Evaluation of DREPADOM - Home Care Services and Hospitalizations for Sickle Cell Disease Patients
NCT05649280 ·Status: COMPLETED
-
Study of Biological Markers in Children With Sickle Cell Disease
NCT04839159 ·Status: UNKNOWN ·Phase: NA
-
Thrombophilia In Beta Thalassemia
NCT04219449 ·Status: NOT_YET_RECRUITING
-
The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation
NCT00789516 ·Status: COMPLETED
-
Biological, Genetic and Environmental Involved in the Complications of Sickle Cell Disease
NCT04205123 ·Status: UNKNOWN
-
Iron Mediated Vascular Disease in Sickle Cell Anemia Patients
NCT01239901 ·Status: COMPLETED
-
Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India
NCT05020873 ·Status: TERMINATED
-
Plasmapheresis: a Multi-modal Approach
NCT05815615 ·Status: COMPLETED ·Phase: NA
-
Effectiveness of Laying-on-of-hands for Sickle Cell Disease
NCT01518218 ·Status: COMPLETED ·Phase: PHASE2
-
Screening Patients With Sickle Cell Disease for Kidney Damage
NCT02239016 ·Status: COMPLETED
-
Pharmacogenetics of VOD in Children With HSCT
NCT03664427 ·Status: COMPLETED
-
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
NCT04925492 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients
NCT05791591 ·Status: COMPLETED ·Phase: NA
-
Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy
NCT04437771 ·Status: ACTIVE_NOT_RECRUITING
-
Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality
NCT03036462 ·Status: COMPLETED ·Phase: PHASE4
-
Risk Factors for Allo-immunization in Sickle Cell Disease
NCT03401125 ·Status: WITHDRAWN
-
5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
NCT00005934 ·Status: COMPLETED ·Phase: PHASE2
-
Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124
NCT04176653 ·Status: WITHDRAWN ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir
NCT05169580 ·Status: COMPLETED ·Phase: PHASE1
-
Genomic Screening for Hereditary Erythrocytosis and Related Diseases
NCT03263364 ·Status: UNKNOWN
-
Specifying Interventions From the Sickle Cell Disease Implementation Consortium (SCDIC)
NCT03380351 ·Status: COMPLETED
-
PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)
NCT03492931 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes
NCT00050843 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacogenetic Study in Patients Received Iron Chelating Agent
NCT01623895 ·Status: COMPLETED
-
The Role of Red Cell Characteristics, Angiogenesis, Viscosity and Oxygenation in the Pathophysiology of Sickle Cell Related Retinopathy
NCT06396403 ·Status: COMPLETED